Cancer Research, Statistics, and Treatment (Jan 2020)

Clinicopathological characteristics, prognostic factors, and outcomes in peripheral T-cell lymphoma: Experience from a single center in India

  • Siva Sree Kesana,
  • Prasanth Ganesan,
  • Tenali Gnana Sagar,
  • Krishnarathinam Kannan,
  • Trivadi S Ganesan,
  • Manikandan Danushkodi,
  • Nikita Mehra,
  • P K Jayachandran,
  • Archit Joshi,
  • Arun Kumar,
  • Gangothri Selvarajan,
  • Shirley Sundersingh,
  • Venkatraman Radhakrishnan

DOI
https://doi.org/10.4103/CRST.CRST_85_19
Journal volume & issue
Vol. 3, no. 1
pp. 3 – 12

Abstract

Read online

Background: Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of diseases with aggressive behavior and inferior outcomes as compared to B-cell lymphomas. We report the outcomes from a single center over a period of 18 years. Methods: The baseline clinical features, pathological subtypes, and prognostic factors of all patients with PTCL treated at our center between January 2000 and December 2017 were retrospectively analyzed. Event-free survival (EFS) and overall survival (OS) were calculated using the Kaplan–Meier method and prognostic factors were compared using the log-rank test. Results: During the study period, 144 patients (2–74 years) were diagnosed with PTCL. Male patients were 101 (70%) and females were 43 (30%). Mean age at diagnosis was 43.5 years (20–74 years) for adults (≥ ≥18 years). Of the 144 patients, 42 (29%) had limited stage (Stage I/II) and 102 (71%) had advanced-stage disease (III/IV). The most common histological diagnosis was PTCL-not otherwise specified observed in 61 patients (42.4%) followed by anaplastic large-cell lymphoma (ALCL) in 65 patients (45.2%). The median duration of follow-up was 70.5 months (range, 1–218 months). Five-year OS and EFS for the entire population were 55% and 33%, respectively. Patients with limited stage had better survival when compared to those with advanced disease. Five-year EFS was 52% versus 25% (P = 0.006) and 5-year OS was 70% versus 47% (P = 0.02) in limited and advanced stage, respectively. Patients with PTCL, anaplastic lymphoma kinase (ALK)-positive ALCL and ALK-negative ALCL had 5-year EFS and OS of 20% and 38%, 46% and 76%, 43% and 76%, respectively (P value for EFS = 0.009 and OS < 0.001). Conclusion: Majority of patients with PTCL at our center presented with advanced-stage disease. Outcomes of patients with ALCL are better than those diagnosed with other subtypes of PTCL.

Keywords